{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T10:54:30Z","timestamp":1648637670598},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1684\/bdc.2013.1792","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:02:13Z","timestamp":1565726533000},"page":"897-902","source":"Crossref","is-referenced-by-count":0,"title":["Rationnel et modalit\u00e9s de prescription du ruxolitinib dans les my\u00e9lofibroses"],"prefix":"10.1016","volume":"100","author":[{"given":"Richard","family":"Lemal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Ravinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Cacheux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1792_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci\u00e9t\u00e9 fran\u00e7aise de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2013.1792_bib0010","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1792_bib0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1684\/bdc.2013.1792_bib0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1684\/bdc.2013.1792_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"10.1684\/bdc.2013.1792_bib0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1792_bib0035","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1792_bib0040","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1792_bib0045","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1684\/bdc.2013.1792_bib0050","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1684\/bdc.2013.1792_bib0055","first-page":"793","article-title":"Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy","volume":"118","author":"Verstovsek","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1684\/bdc.2013.1792_bib0060","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1684\/bdc.2013.1792_bib0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1792_bib0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1792_bib0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","author":"Verstovsek","year":"2012","journal-title":"Blood [Internet]"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115302290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115302290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:25:57Z","timestamp":1602491157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115302290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0007455115302290"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1792","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}